Hansoh Pharmaceutical Group (HKG:3692) said an additional indication of Ameile was granted registration approval by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The additional indication is for use of the drug in combination with pemetrexed and platinum-
based chemotherapy to treat adult patients with locally advanced or metastatic non-small cell lung cancer.
This is the fifth indication of the drug which has been approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments